Gregory Otterson

Gregory Otterson, MD

Physician

Make an Appointment

Overall Patient Satisfaction Rating

stars
4.8 out of 5
102
Reviews
1
Comments

Gender

Male

Biography


I’m a thoracic oncologist dedicated to advancing the care and treatment of patients with thoracic malignancies – such as adenocarcinoma, mesothelioma and thymic cancers – by helping develop novel therapeutic approaches to these diseases. Such treatments range from combinations of conventional cytotoxic chemotherapy, novel targeted agents and immunotherapy applied to patients with early stage or advanced disease. I was named to the Castle Connolly list of “Regional Top Doctors” from 2006-2019 and rated in the top 10 percent of physicians in the nation for patient satisfaction in 2017.

I am a professor of internal medicine, associate division director for education in the Division of Medical Oncology, associate program director of the Hematology/Oncology Fellowship Program and clinical director of the Thoracic Oncology Disease Specific Research Group at OSUCCC – James. I serve on the National Comprehensive Cancer Network (NCCN) nonsmall cell lung cancer guidelines panel.

At The James, we have a true multi-disciplinary team in thoracic oncology that includes medical oncologists, thoracic surgeons, radiation oncologists, pulmonologists, pathologists, radiologists, nurses, pharmacists, nurse practitioners and physician assistants. Together we work to continually improve patients’ quality of life and develop effective therapies in an effort to end cancer.

Education and Background

Education

Georgetown University School of Medicine

Washington, DC

Residencies

Rush-Presbyterian-St.Luke's Med Ctr

Chicago, IL

Fellowship

Medical Oncology

National Cancer Institute

Bethesda, MD

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

Academic Department

Department of Internal Medicine

Division of Medical Oncology


Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 11/21/2019, Dr. Otterson has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.

Guardant Health

Reviews

Patient Satisfaction Review

The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page

The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.

Overall Ratings (out of 102 reviews)
stars
4.8 out of 5
Kept you informed about your condition and treatment

4.8/ 5

Amount of time spent with you

4.7/ 5

Concern for your questions and issues

4.7/ 5

Skill and knowledge

4.8/ 5

Overall quality of care

4.8/ 5

Patient Comments (2 total comments)

stars
Reviewed: 9/30/2019

Great.

stars
Reviewed: 7/27/2019

good

Publications

Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung specific transgenic mice.

Duan W, Gao L, Kalvala A, Aguila B, Brooks C, Mo X, Ding H, Shilo K, Otterson GA, Villalona-Calero MA

Int J Cancer in press

3/15/2019

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS

J Clin Oncol in press

2/20/2019

Clinical Trials | Lead

RTOG-1008

ECOG-ACRIN-EA5163

ECOG-E4512

Back to Find a Doctor Search

Make an Appointment

800-293-5066

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

OR

Please enter a keyword (i.e. Name, Location) or choose a Cancer Type

OR